Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort.

Details

Ressource 1Download: 37679749_BIB_78E6FABD54DF.pdf (1050.77 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_78E6FABD54DF
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Disease evolution in systemic juvenile idiopathic arthritis: an international, observational cohort study through JIRcohort.
Journal
Pediatric rheumatology online journal
Author(s)
Wallimann M., Bouayed K., Cannizzaro E., Kaiser D., Belot A., Merlin E., Poignant S., Wouters C., Hofer F., Saurenmann T., Koryllou A., Carlomagno R., Mejbri M., Hofer M., Theodoropoulou K.
ISSN
1546-0096 (Electronic)
ISSN-L
1546-0096
Publication state
Published
Issued date
07/09/2023
Peer-reviewed
Oui
Volume
21
Number
1
Pages
96
Language
english
Notes
Publication types: Observational Study ; Journal Article
Publication Status: epublish
Abstract
Systemic juvenile idiopathic arthritis (systemic JIA) is a severe disease with both systemic and joint inflammation. This study aims to identify predictors of disease evolution within the systemic JIA population enrolled in the Juvenile Inflammatory Rheumatism cohort (JIRcohort).
Observational patient cohort study with 201 recruited children from 4 countries (3 European, 1 North Africa) from 2005 until 2019, using retrospectively (2005-2015) and prospectively (2015-2019) routine care collected data.
Sixty-five patients with complete follow-up data for 24 months after first diagnosis were classified as monophasic (n = 23), polyphasic (n = 6) or persistent group (n = 36) corresponding to their evolution (unique flare, recurrent flares, or persistent disease activity respectively). The patients of the persistent group were more likely to have an earlier disease onset, before the age of 6 (OR 2.57, 95%-CI 0.70-9.46), persistence of arthritis at 12-months post-diagnosis (OR 4.45, 95%-CI 0.58-34.20) and higher use of synthetic DMARD (sDMARD, OR 5.28, 95%-CI 1.39-20.01). Other variables like global assessment by physician and by patient and C Reactive Protein levels at 12-months post-diagnosis were assessed but without any predictive value after adjusting for confounding factors.
Our results suggest that the earlier disease onset, the persistence of arthritis throughout the first year of disease evolution and the need of sDMARD might predict a persistent disease course.
Keywords
Child, Humans, Arthritis, Juvenile/drug therapy, Retrospective Studies, Antirheumatic Agents/therapeutic use, Cohort Studies, Data Collection, Biologics, Outcome, Predictors, Systemic onset juvenile idiopathic arthritis, Treatment
Pubmed
Web of science
Open Access
Yes
Create date
25/09/2023 15:04
Last modification date
08/08/2024 6:35
Usage data